Sign in
NeurosciencebioRxiv
Preprint

α-synuclein over expression, NRF2 suppression, and enhanced ferroptosis creates a vicious cycle of neuronal loss in Parkinson's disease

Annadurai AnandhaniD, W Chen, Lan Ngoc-NguyeniD, Lalitha MadhavaniD, Matthew B. DodsoniD, D.D. Zhang

Abstract

Parkinsons disease (PD) is the second most common neurodegenerative disorder, affecting millions each year. Most PD cases ([~]90%) are sporadic, resulting from the age-dependent accumulation of pathogenic effects. One key pathological hallmark of PD progression is the accumulation of alpha-synuclein (-syn), which has been shown to negatively affect neuronal function and viability. Here, using 3- and 6-month-old Nrf2+/+ and Nrf2-/- mice overexpressing human -syn (PD model), we show that loss of NRF2 increases markers of ferroptosis across PD-relevant brain regions. Increased ferroptosis was associated with an age- and genotype-dependent increase in -syn pathology and behavioral deficits. Finally, we demonstrate that -syn overexpression sensitizes neuronal cells and ex vivo brain slices to ferroptosis induction, which may be due to -syn suppression of NRF2 at the protein level. Altogether, these results indicate that NRF2 is a critical anti-ferroptotic mediator of neuronal survival, and that the vicious cycle of -syn overexpression and NRF2 suppression, leading to enhanced neuronal ferroptotic cell death, could represent a targetable and currently untapped means of preventing PD onset and progression.

PDFDOI
Structured summary ↓

02 /Specification & Classification

Click any tag to browse matching papers
Citations
48
FWCI
5.66
Field percentile
top 3%

Abstract summary

Verified abstract synthesis

Claude Opus 5.5 · xhigh effort · 2 Nov 2026 · from the abstract

In Parkinson's disease models, alpha-synuclein overexpression sensitizes neurons to ferroptosis, potentially by suppressing NRF2 protein, while Nrf2 loss increases ferroptosis markers, alpha-synuclein pathology, and behavioral deficits.

Roughly 90% of Parkinson's disease (PD) cases are sporadic and characterized by age-dependent pathogenic accumulation of alpha-synuclein that impairs neuronal viability. By studying mice overexpressing human alpha-synuclein alongside neuronal cells and ex vivo brain slices, this work identifies a self-reinforcing loop linking alpha-synuclein accumulation, NRF2 suppression, and ferroptotic neuronal death.

Key results

  1. ShownGenetic loss of Nrf2 elevates ferroptosis markers across PD-relevant brain regions and worsens alpha-synuclein pathology and behavioral deficits in an age- and genotype-dependent manner.

    Shown in 3- and 6-month-old Nrf2+/+ and Nrf2-/- mice overexpressing human alpha-synuclein (no specific animal counts or effect sizes are reported in the abstract). · Abstract

  2. ShownOverexpression of alpha-synuclein increases susceptibility to ferroptosis induction in neuronal cells and ex vivo brain slices, potentially via protein-level NRF2 suppression.

    Demonstrated in neuronal cells and ex vivo brain slices overexpressing alpha-synuclein (no numerical measurements are provided in the abstract). · Abstract

Methods, data and reproducibility

The authors evaluated ferroptosis markers, alpha-synuclein pathology, and behavioral deficits across PD-relevant brain regions in 3- and 6-month-old Nrf2+/+ and Nrf2-/- mice overexpressing human alpha-synuclein. They also tested susceptibility to ferroptosis induction and NRF2 protein suppression upon alpha-synuclein overexpression in neuronal cells and ex vivo brain slices.

  • 3- and 6-month-old Nrf2+/+ and Nrf2-/- mice overexpressing human alpha-synuclein · mouse (expressing human alpha-synuclein)
  • Neuronal cells and ex vivo brain slices overexpressing alpha-synuclein
Reproducibility gaps
Sample sizes, specific ferroptosis markers, behavioral assay names, and data repositories are not stated in the abstract.
Limitations (2)
  • All reported findings rely on Nrf2+/+ and Nrf2-/- mice, ex vivo brain slices, and neuronal cells overexpressing alpha-synuclein, without direct validation in human Parkinson's disease patient tissue. · noted in this summary
  • Whether targeting the alpha-synuclein–NRF2–ferroptosis loop prevents Parkinson's disease onset or progression is proposed as a therapeutic concept rather than tested with an intervention in the abstract. · noted in this summary

Who should read:Read this if you study neurodegeneration or Parkinson's disease mechanisms and want evidence linking alpha-synuclein toxicity to NRF2 suppression and ferroptotic cell death.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISDelaidelli '21Nicolau '26Bieri '19Huang '25Mahoney‐San '25Andersen '19
83% semantic matchNeuroscience
Alberto Delaidelli, Mette Richner, Lixiang Jiang+9 more·Acta Neuropathologica Communications·Jun 6, 2021· 39 citations